

Bronchial Thermoplasty Under General Anesthesia Using Second Generation Supraglottic Airway Device (Ambu® Auragain): A Case Series

Ovidiu Vornicu^{1*}, Anne-Sophie Dincq^{1*}, Alain Mayné¹, Jean-Paul d'Odémont², Jean-Louis Mariage³ and Laurie Putz¹

¹Department of Anesthesiology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

²Department of Pneumology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium

³Department of Intensive Care, Centre Hospitalier de Mouscron, Mouscron, Belgium

Corresponding Author: Anne-Sophie Dincq, Department of Anesthesiology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.

*Ovidiu Vornicu and Anne-Sophie Dincq contributed equally

Received: September 04, 2017; **Published:** September 20, 2017

Abstract

Bronchial thermoplasty is an emerging interventional bronchoscopic procedure aimed at helping patients with moderate to severe asthma. This treatment delivers thermal energy to the bronchial wall during bronchoscopies which leads to an improvement in asthma escaping to conventional pharmacological treatment. Bronchial thermoplasty is performed under mild or deep sedation or general anesthesia requiring tracheal intubation or laryngeal mask insertion. However, sedation presents some secondary effects such as coughing, apnea and patient and/or pneumologist discomfort while general anesthesia with intubation is more invasive and is associated with potentially harmful hemodynamic instability. We therefore decided to perform bronchial thermoplasty with a second-generation supraglottic airway device: Ambu® AuraGain (Ambu A/S, Ballerup, Denmark). This device is anatomically curved and offers a higher seal pressure as well as a clear view of the glottis inlet. Here, we report the use of a second-generation supraglottic airway device (Ambu® AuraGain) in four patients undergoing 12 procedures.

Keywords: Bronchial Thermoplasty; General Anesthesia; Supraglottic Airway Device

Abbreviations

BT: Bronchial Thermoplasty; FiO₂: Fraction of Inspired Oxygen; GA: General Anesthesia; NMT: Neuromuscular Transmission; RF: Radio-frequency; SaO₂: Blood Gas Analysis Blood Saturation; SpO₂: Continuous Pulse Oximetry; TCI: Target Control Infusion

Introduction

Bronchial thermoplasty (BT) is an emerging interventional bronchoscopic procedure aimed at helping patients who are suffering from moderate to severe asthma. This treatment results in an improvement in asthma control [1]. In asthma, the airway smooth muscle has an increased contractility leading to bronchoconstriction as well as an increased mass leading to a remodeling of the airway with functional consequences. Long acting β_2 -agonists are the first line of treatment. Adjunction of anti-inflammatory agents including high-dose oral corticoids leads to long term stability in the majority of patients. Sometimes, the medication doesn't work hence the idea of a non-pharmacological approach by delivering thermal energy during bronchoscopies to induce a prolonged reduction of the airway smooth-muscle mass along with improved contractility [2] and a hypothetically decreased secretion of inflammatory mediators by airway smooth muscle cells [3].

Citation: Anne-Sophie Dincq, *et al.* "Bronchial Thermoplasty Under General Anesthesia Using Second Generation Supraglottic Airway Device (Ambu® Auragain): A Case Series". *EC Anaesthesia* 3.2 (2017): 44-49.

BT is performed under mild or deep sedation [4,5] or general anesthesia (GA) requiring tracheal intubation or laryngeal mask insertion [6]. However, sedation can be unsatisfactory as coughing and apnea do occur, causing patient and/or bronchoscopist discomfort while GA with intubation is more invasive and carries the potential risk of harmful hemodynamic instability [7]. We therefore decide to perform BT with a second- generation supraglottic airway device: Ambu® AuraGain (Ambu A/S, Ballerup, Denmark). This device is anatomically curved and offers a wider integrated gastric access channel compared with other supraglottic devices [8]. Furthermore, it offers a higher seal pressure and a clear view of the glottis inlet in all patients. This enhanced visibility of the glottis inlet allows us to guide direct tracheal intubation if required [9]. The use of a second- generation supraglottic airway device (Ambu® AuraGain) in 4 patients undergoing 12 BT procedures is herein reported.

Materials and Methods

Case series presentation

Ethical committee number B3920154170 and ANZCTR number ACTRN12615001198516 were assigned to this case series. All patients gave written informed consent. Four patients scheduled for BT based on the criteria used in the Asthma Intervention Research 2 Trial Study [10] were enrolled. A total of 12 procedures were studied.

BT consists of the cautious application during bronchoscopy of radiofrequency (RF) electrical energy to the airway wall especially since there are no macroscopic signs with the exception of temporary bleaching of the mucosa [3]. BT is performed using the Alair Bronchial Thermoplasty System (Boston Scientific, Natick, MA, USA) comprising the Alair RF generator and the catheter electrode that is inserted in the flexible bronchoscope.

Performing BT requires dexterity, a good knowledge of the airway anatomy and an excellent direct endoscopic vision. A full treatment consists of 30 to 70 activations per treatment, at least 3 weeks apart. Each activation targeting a 5 mm zone of bronchus with a diameter between 3 and 10 mm. The time duration of each session is around 60 minutes [11]. The order of lobe treatment during bronchoscopy is: right lower (BT 1), left lower (BT 2) and right and left upper (BT 3) during the last procedure [12]. Regarding the right middle lobe, no experience have to date been reported due to potential and theoretical concern about middle lobe syndrome [13]. This entity is characterized by recurrent or chronic collapse of the middle right lobe, which is often related to asthma [14].

In addition to the patient's chronic treatment, the daily oral corticoid dose was increased to 32 mg of methylprednisolone three days prior to the BT session in order to minimize post-procedural inflammation. Premedication consisted of 0.5 mg of alprazolam PO. After using the World Health Organization Checklist [15] including an assessment of adequate fasting to avoid pulmonary aspiration, appropriate monitoring was applied including: 3-lead electrocardiogram, continuous pulse oximetry (SpO₂), noninvasive blood pressure, depth of anesthesia and neuromuscular transmission (NMT) monitoring. General anesthesia was accomplished with remifentanyl and propofol via Target Control Infusion (TCI). During maintenance the infusion was adapted according to the hemodynamic response and a bispectral index between 40 and 60. As soon as the patient lost consciousness and manual ventilation was possible, a bolus dose of rocuronium of 0,6 mg/kg was administered to achieve deep neuromuscular relaxation (post-tetanic count 1 - 2) [16] not only during the Ambu® AuraGain insertion but also during the entire procedure to ensure immobilization, vocal cord adduction and prevention of patient coughing. Patients also received 2 mg/kg of methylprednisolone, 2 gr of magnesium sulfate and 0.5 mg epinephrine tartrate SC in order to improve bronchodilatation [17]. After induction, invasive arterial pressure by radial artery cannulation was performed and blood gas analyses were carried out at 15 minutes intervals. The size of the Ambu® AuraGain was selected according to the manufacturer's recommendations: size 4 for a body weight between 50 and 70 kg and size 5 for a body weight between 70 and 100 kg; it was inserted completely deflated and lubricated with sterile saline. A manometer was used to inflate the cuff. Ventilation was achieved with volume-controlled ventilation AutoFlow: all the breaths were pressure-controlled, with a delivered level of support-peak pressure alarm - that varies from breath to breath to deliver the set tidal volume [18] - 6 to 8 ml/kg to achieve an end tidal CO₂ between 35 and 40 mmHg. The fraction of

inspired oxygen (FiO₂) is adjusted according to the result of SpO₂ and the result of blood gas analysis blood saturation (SaO₂). Inspiration/Expiration time (I/E) was maintained between 1:2 and 1:3. Arterial saturation below 93% was defined as desaturation. Analgesia was achieved with paracetamol and tramadol. At the end of the BT, propofol and remifentanyl infusions were stopped. Residual neuromuscular block was counteracted by sugammadex at a dose of 4mg/kg to achieve a train of four ratio above 90% [16]. Once spontaneous respiration resumed, the Ambu® AuraGain was removed and the patient was taken to the recovery room. Patients were monitored in the recovery room for at least 2 hours. Blood gas analyses were performed upon arrival and upon discharge. Inhaled aerosols (ipratropium bromide/ fenoterol bromhydrate: 0.5 mg/1.25 mg and epinephrine tartrate 0.5 mg) were administered upon arrival. Post-procedure stay was 3 days to avoid re-admission reported in other studies [19,20].

Results and Discussion

All the Ambu® AuraGain devices were introduced at the first attempt, with no mucosal trauma. Blood gas analyses showed decreased PaO₂/FiO₂ in 10 sessions at the end of the procedure (Figure 1).




Figure 1: (Patient 1-4): Evolution of PaO₂/FiO₂ during the 3 sessions in each patient.

SpO₂ was never below 93% for FiO₂ between 0.45 and 0.7 during BT. In the recovery room, no severe acidosis was recorded (pH below 7.25), PaCO₂ was between 31 mmhg and 45 mmhg and no desaturation was observed. All the sessions were performed without interruption for coughing episodes, bronchoscopist discomfort or other intercurrent problems. No BT procedures were delayed for asthma exacerbation or infection. No intra-hospital event were recorded and there were no readmissions to the hospital in the following 7 days.

BT is performed with a wide range levels of sedation ranging from mild sedation with midazolam and fentanyl [5], TCI of propofol combined with remifentanyl [21] or dexmedetomidine or deep propofol sedation [4] or general anesthesia with supraglottic device or tracheal intubation [6].

Wang., *et al.* recently highlighted the suitability to performing BT with controlled ventilation with improved laryngeal mask airway compared to high-frequency jet ventilation through Wei jet nasal airway [8]. Second -generation supraglottic devices besides to offering a gastric access allowing a possible gastric tube placement allowing an active gastric content suction, haven proven seal pressure up to 40 cmH20. This high seal pressure is ensured with low cuff inflation which reduces the trauma caused by pressure on soft tissue. In our series, the seal pressure achieved was deemed adequate to deliver ventilation in accordance with the predefined parameters (described above) in all the asthmatic patients. Adequate steal pressure was deemed correct by the absence of leaks around the procedure site. It should be borne in mind that during BT, a flexible bronchoscope is inserted via a Mainz connector and surrounding leakage can occur leading to unstable mechanical ventilation, hence the choice of intravenous anesthesia. An interesting device that could be used in the future, involves fusing a flexible catheter mount to a laparoscopic trocar used as an adaptor to solve the issue of air leakage occurring dur-

ing bronchoscopy performed under general anesthesia [22] Supraglottic devices have also yielded a reduction in laryngospasm during emergence, a reduction in postoperative hoarse voice and coughing compared with endotracheal intubation [23]. Also, in the asthmatic population, when regional anesthesia is unavoidable, supraglottic devices have been found to be safer when compared to tracheal intubation, which offers a further argument favoring this type of device [24].

In our patients, all the Ambu® AuraGain devices were easily inserted at the first attempt with no mucosal trauma [25]. General anesthesia was also beneficial in reducing anxiety and pain due to activations by the BT catheters and the level of respiratory distress compared to local anesthesia or mild sedation [26,27]. Bronchoscopist was pleased with the working conditions including absence of coughing episodes, movement and easy insertion of the flexible bronchoscope helped by a good glottis inlet thanks to the supraglottic device.

The mean time duration of the 3 BT sessions we recorded (between 26 and 73 minutes) knowing that BT3 sessions were always longer as they concerned 2 lobes, was in accordance with literature, the mean procedure duration reported being between 40 and 60 minutes [11]. As regards the blood gas analysis, we also reported a reduction of the $\text{PaO}_2/\text{FiO}_2$ throughout the procedure with no severe desaturation or bronchospasm. The underlying involved mechanism is assigned to an increased bronchic hyperactivity due to thermal aggression by BT catheter and the procedure itself [28].

Conclusion

In accordance with the American College of Chest Physicians consensus statement, suggesting that all physicians who perform bronchoscopy should use topical anesthetic, analgesic and sedative agents when feasible, we reported our small single-center experience describing the feasibility of BT under general anesthesia [29]. Total intravenous anesthesia is reported with deep neuromuscular block and the insertion of second-generation Ambu® AuraGain supraglottic airway devices. All the supraglottic devices were inserted at the first attempt without mucosal trauma and with a seal pressure allowing volume-controlled ventilation in severe asthmatic patients. The bronchoscopist's working conditions were described as excellent among others things because of the strict immobility of the patient allowing the realization of this high precision procedure and the easy flexible bronchoscope insertion through the supraglottic airway device. No severe desaturation, no episodes of coughing and no asthma attacks being reported during the procedure. The type of anesthesia during BT is still matter in debate and require further large-scale studies.

Acknowledgements

The authors thank Dr Elizabeth Wager for language editing and Pr. O. Vandenplas for his pre and post-operative management of patients.

Conflict of Interest

None.

Bibliography

1. Cox G., *et al.* "Asthma control during the year after bronchial thermoplasty". *New England Journal of Medicine* 356.13 (2007): 1327-1337.
2. Dyrda P., *et al.* "Acute response of airway muscle to extreme temperature includes disruption of actin-myosin interactio". *American Journal of Respiratory Cell and Molecular Biology* 44.2 (2011): 213-221.
3. Dombret MC., *et al.* "Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults". *European Respiratory Review* 23.134 (2014): 510-518.
4. Lee JA., *et al.* "Bronchial thermoplasty: a novel treatment for severe asthma requiring monitored anesthesia care". *AANA Journal* 79.6 (2011): 480-483.

5. Mayse M., *et al.* "Clinical Peral for Bronchial Thermoplasty". *Journal of Bronchology and Interventional Pulmonology* 14.2 (2007): 115-223.
6. Pawlowski J. "Anesthetic considerations for interventional pulmonary procedures". *Current Opinion in Anaesthesiology* 26.1 (2013): 6-12.
7. Brimacombe J. "The advantages of the LMA over the tracheal tube or facemask: a meta-analysis". *Canadian Journal of Anesthesia* 42.11 (1995): 1017-1023.
8. Wang W., *et al.* "Comparison of the Effectiveness of Different Supraglottic Ventilation Methods during Bronchial Thermoplasty". *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 38.2 (2016): 131-135.
9. Eccher M., *et al.* "To the editor". *Journal of Clinical Monitoring and Computing* 29.2 (2015): 313-314.
10. Castro M., *et al.* "Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial". *American Journal of Respiratory and Critical Care Medicine* 181.2 (2010): 116-124.
11. Singh SK., *et al.* "Bronchial thermoplasty: a non-pharmacological approach". *Clinical Respiratory Journal* 11.1 (2017): 13-20.
12. Cox G., *et al.* "Bronchial thermoplasty for asthma". *American Journal of Respiratory and Critical Care Medicine* 173.9 (2006): 965-969.
13. Gudbjartsson T., *et al.* "Middle lobe syndrome: a review of clinicopathological features, diagnosis and treatment". *Respiration* 84.1 (2012): 80-86.
14. Springer C., *et al.* "Role of infection in the middle lobe syndrome in asthma". *Archives of Disease in Childhood* 67.5 (1992): 592-594.
15. Haynes AB., *et al.* "A surgical safety checklist to reduce morbidity and mortality in a global population". *New England Journal of Medicine* 360.5 (2009): 491-499.
16. Dubois PE., *et al.* "A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium". *Acta Anaesthesiologica Belgica* 64.2 (2013): 49-60.
17. Rowe BH., *et al.* "Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature". *Annals of Emergency Medicine* 36.3 (2000): 181-190.
18. Lasocki S., *et al.* "A long-term clinical evaluation of autoflow during assist-controlled ventilation: a randomized controlled trial". *Anesthesia and Analgesia* 111.4 (2010): 915-921.
19. Pavord ID., *et al.* "Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma". *American Journal of Respiratory and Critical Care Medicine* 176.12 (2007): 1185-1191.
20. Thomson NC., *et al.* "Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial". *BMC Pulmonary Medicine* 11 (2011): 8.
21. d'Hooghe JN. "Propofol and Remifentanyl Sedation for Bronchial Thermoplasty: A Prospective Cohort Trial". *Respiration* 93.1 (2017): 58-64.
22. Choi JH., *et al.* "Application of Ventilating-Bronchoscopy-Adaptor by Fusing a Laparoscopic Trocar during Bronchial Thermoplasty under General Anesthesia". *Yonsei Medical Journal* 57.2 (2016): 534-535.
23. Yu SH., *et al.* "Laryngeal mask airways have a lower risk of airway complications compared with endotracheal intubation: a systematic review". *Journal of Oral and Maxillofacial Surgery* 68.10 (2010): 2359-2376.

24. Burburan SM., *et al.* "Anaesthetic management in asthma". *Minerva Anestesiologica* 73.6 (2007): 357-365.
25. Ueshima H., *et al.* "Use of the new supraglottic device "Ambu AuraGain" in clinical settings". *Journal of Clinical Anesthesia* 31 (2016): 263-264.
26. Putinati S., *et al.* "Patient satisfaction with conscious sedation for bronchoscopy". *Chest* 115.5 (1999): 1437-1440.
27. Heinen V., *et al.* "Bronchial thermoplasty: a real advancement in the treatment of asthma". *Revue Médicale Suisse* 10.439 (2014): 1544,1546-1548.
28. Chanez P., *et al.* "Bronchial thermoplasty in the treatment of severe adult asthma". *Revue des Maladies Respiratoires* 32.2 (2015): 97-109.
29. Wahidi MM., *et al.* "American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients". *Chest* 140.5 (2011): 1342-1350.

Volume 3 Issue 2 September 2017

© All rights reserved by Anne-Sophie Dincq., *et al.*